Home LiteratureArticle Details
PMID: 937081 Published · ppublish English Case Reports Journal Article

Interferon therapy in Hodgkin's disease. A case report.

Acta medica Scandinavica ·Vol. 199 ·No. 6 ·1976-00-00 ·Pages 527-32

Blomgren H, Cantell K, Johansson B, Lagergren C, Ringborg U, Strander H

Abstract

The treatment of a case of Hodgkin's disease (lymphocyte predominance, stage IV B) with exogenous i.m. interferon therapy is described. B symptoms disappeared, diseased nodes and pulmonary infiltrations decreased in size, and laboratory values normalized. Clinical improvement was associated with increased mitogenic responsiveness of the patient's lymphocytes towards various stimuli in vitro. After almost half a year's treatment tumour progression and a decreased mitogenic response were again observed. Interferon treatment was then abandoned and combined cytostatic courses were instituted. Partial remission was achieved after 6 months of cytostatic therapy, i.e. 1 year after the start of treatment.

MeSH Terms
Adult Antineoplastic Agents/therapeutic use Concanavalin A/pharmacology Drug Therapy, Combination Hodgkin Disease/drug therapy Humans Interferons/therapeutic use Lectins/pharmacology Lymphocyte Activation/drug effects Male Mitogens/pharmacology
Chemicals
Antineoplastic Agents Lectins Mitogens Concanavalin A Interferons
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Blomgren H
Cantell K
Johansson B
Lagergren C
Ringborg U
Strander H
Article Info
Journal
Acta medica Scandinavica
Abbr.
Acta Med Scand
ISSN
0001-6101
Published
1976-00-00
Pages
527-32
Language
English
Region
Sweden
NLM ID
0370330
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]